Literature DB >> 19690135

Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression.

Jitesh Pratap1, Karen M Imbalzano, Jean M Underwood, Nathalie Cohet, Karthiga Gokul, Jacqueline Akech, Andre J van Wijnen, Janet L Stein, Anthony N Imbalzano, Jeffrey A Nickerson, Jane B Lian, Gary S Stein.   

Abstract

The transcription factor Runx2 is highly expressed in breast cancer cells compared with mammary epithelial cells and contributes to metastasis. Here we directly show that Runx2 expression promotes a tumor cell phenotype of mammary acini in three-dimensional culture. Human mammary epithelial cells (MCF-10A) form polarized, growth-arrested, acini-like structures with glandular architecture. The ectopic expression of Runx2 disrupts acini formation, and electron microscopic ultrastructural analysis revealed the absence of lumens. Characterization of the disrupted acini structures showed increased cell proliferation (Ki-67 positive cells), decreased apoptosis (Bcl-2 induction), and loss of basement membrane formation (absence of beta(4) integrin expression). In complementary experiments, inhibition of Runx2 function in metastatic MDA-MB-231 breast cancer cells by stable expression of either short hairpin RNA-Runx2 or a mutant Runx2 deficient in subnuclear targeting resulted in reversion of acini to more normal structures and reduced tumor growth in vivo. These novel findings provide direct mechanistic evidence for the biological activity of Runx2, dependent on its subnuclear localization, in promoting early events of breast cancer progression and suggest a molecular therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690135      PMCID: PMC2742766          DOI: 10.1158/0008-5472.CAN-09-1471

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini.

Authors:  Jayanta Debnath; Kenna R Mills; Nicole L Collins; Mauricio J Reginato; Senthil K Muthuswamy; Joan S Brugge
Journal:  Cell       Date:  2002-10-04       Impact factor: 41.582

2.  Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development.

Authors:  J Y Choi; J Pratap; A Javed; S K Zaidi; L Xing; E Balint; S Dalamangas; B Boyce; A J van Wijnen; J B Lian; J L Stein; S N Jones; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Authors:  Jayanta Debnath; Senthil K Muthuswamy; Joan S Brugge
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

4.  Constitutive expression and regulation of collagenase-3 in human breast cancer cells.

Authors:  N Selvamurugan; N C Partridge
Journal:  Mol Cell Biol Res Commun       Date:  2000-04

5.  Causal relationship between the loss of RUNX3 expression and gastric cancer.

Authors:  Qing Lin Li; Kosei Ito; Chohei Sakakura; Hiroshi Fukamachi; Ken ichi Inoue; Xin Zi Chi; Kwang Youl Lee; Shintaro Nomura; Chang Woo Lee; Sang Bae Han; Hwan Mook Kim; Wun Jae Kim; Hiromitsu Yamamoto; Namiko Yamashita; Takashi Yano; Toshio Ikeda; Shigeyoshi Itohara; Johji Inazawa; Tatsuo Abe; Akeo Hagiwara; Hisakazu Yamagishi; Asako Ooe; Atsushi Kaneda; Takashi Sugimura; Toshikazu Ushijima; Suk Chul Bae; Yoshiaki Ito
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

6.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini.

Authors:  S K Muthuswamy; D Li; S Lelievre; M J Bissell; J S Brugge
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

7.  Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.

Authors:  Kristen D Brubaker; Robert L Vessella; Lisha G Brown; Eva Corey
Journal:  Prostate       Date:  2003-06-15       Impact factor: 4.104

8.  Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.

Authors:  Fei Wang; Rhonda K Hansen; Derek Radisky; Toshiyuki Yoneda; Mary Helen Barcellos-Hoff; Ole W Petersen; Eva A Turley; Mina J Bissell
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

9.  Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2.

Authors:  Guozhi Xiao; Di Jiang; Rajaram Gopalakrishnan; Renny T Franceschi
Journal:  J Biol Chem       Date:  2002-08-28       Impact factor: 5.157

10.  Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD complex to promote osteoblast differentiation.

Authors:  Amjad Javed; Faiza Afzal; Jong-Sup Bae; Soraya Gutierrez; Kaleem Zaidi; Jitesh Pratap; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Cells Tissues Organs       Date:  2008-08-26       Impact factor: 2.481

View more
  51 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

3.  Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model.

Authors:  Yaojuan Lu; Steven Gitelis; Guanghua Lei; Ming Ding; Carl Maki; Ranim R Mira; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

4.  Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells.

Authors:  S K Baniwal; P K Shah; Y Shi; J H Haduong; Y A Declerck; Y Gabet; B Frenkel
Journal:  Osteoporos Int       Date:  2011-09-01       Impact factor: 4.507

5.  Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.

Authors:  Hanna Taipaleenmäki; Gillian Browne; Jacqueline Akech; Jozef Zustin; Andre J van Wijnen; Janet L Stein; Eric Hesse; Gary S Stein; Jane B Lian
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

6.  Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.

Authors:  Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

Review 7.  Nuclear organization mediates cancer-compromised genetic and epigenetic control.

Authors:  Sayyed K Zaidi; Andrew J Fritz; Kirsten M Tracy; Jonathan A Gordon; Coralee E Tye; Joseph Boyd; Andre J Van Wijnen; Jeffrey A Nickerson; Antony N Imbalzano; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  Adv Biol Regul       Date:  2018-05-09

8.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

9.  Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.

Authors:  Saba Mohamed El-Gendi; Mohamed Farouk Mostafa
Journal:  Pathol Oncol Res       Date:  2015-11-23       Impact factor: 3.201

Review 10.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.